Sonrotoclax: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Sonrotoclax, a B-cell lymphoma-2 inhibitor, is now conditionally approved in China for treating specific B-cell malignancies. This approval marks a significant milestone for patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia and mantle cell lymphoma.
Area of Science:
- Oncology
- Pharmacology
Background:
- Sonrotoclax is a novel small-molecule B-cell lymphoma-2 (BCL-2) inhibitor.
- It is being developed for the treatment of various B-cell malignancies.
Purpose of the Study:
- To summarize the development milestones of sonrotoclax.
- To highlight its first conditional approval in China.
Main Methods:
- Review of clinical development data for sonrotoclax.
- Analysis of regulatory submission and approval process.
Main Results:
- Sonrotoclax received conditional approval in China on January 6, 2026.
- Approval is for adult patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic leukaemia (SLL) and relapsed or refractory mantle cell lymphoma (MCL) who have undergone prior Bruton's tyrosine kinase (BTK) inhibitor therapy.
Conclusions:
- Sonrotoclax represents a new therapeutic option for specific relapsed/refractory B-cell malignancies.
- This approval signifies a key advancement in B-cell cancer treatment.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Treatment Resistent Cancers
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Clearance: Overview
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
